Innoviva Other Non-Current Liabilities 2012-2026 | INVA
Innoviva other non-current liabilities from 2012 to 2026. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
|
Innoviva Annual Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2025 | $123 |
| 2024 | $118 |
| 2023 | $84 |
| 2022 | $81 |
| 2021 | |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $1 |
| 2017 | $1 |
| 2016 | $1 |
| 2015 | $2 |
| 2014 | $2 |
| 2013 | |
| 2012 | |
| 2011 | |
|
Innoviva Quarterly Other Non-Current Liabilities (Millions of US $) |
|
|---|---|
| 2026-03-31 | $127 |
| 2025-09-30 | $113 |
| 2025-06-30 | $115 |
| 2025-03-31 | $116 |
| 2024-12-31 | $118 |
| 2024-09-30 | $83 |
| 2024-06-30 | $84 |
| 2024-03-31 | $83 |
| 2023-12-31 | $84 |
| 2023-09-30 | $79 |
| 2023-06-30 | $79 |
| 2023-03-31 | $80 |
| 2022-12-31 | $81 |
| 2022-09-30 | $78 |
| 2022-06-30 | |
| 2022-03-31 | |
| 2021-12-31 | |
| 2021-09-30 | $0 |
| 2021-06-30 | $0 |
| 2021-03-31 | $0 |
| 2020-12-31 | $0 |
| 2020-09-30 | $0 |
| 2020-06-30 | $0 |
| 2020-03-31 | $0 |
| 2019-12-31 | $0 |
| 2019-09-30 | $0 |
| 2019-06-30 | $0 |
| 2019-03-31 | $0 |
| 2018-12-31 | $1 |
| 2018-09-30 | $1 |
| 2018-06-30 | $1 |
| 2018-03-31 | $1 |
| 2017-12-31 | $1 |
| 2017-09-30 | $1 |
| 2017-06-30 | $1 |
| 2017-03-31 | $1 |
| 2016-12-31 | $1 |
| 2016-09-30 | $2 |
| 2016-06-30 | $2 |
| 2016-03-31 | $2 |
| 2015-12-31 | $2 |
| 2015-09-30 | $2 |
| 2015-06-30 | $2 |
| 2015-03-31 | $2 |
| 2014-12-31 | $2 |
| 2014-09-30 | $2 |
| 2014-06-30 | $1 |
| 2014-03-31 | |
| 2013-12-31 | |
| 2013-09-30 | |
| 2013-06-30 | |
| 2013-03-31 | |
| 2012-12-31 | |
| 2012-09-30 | |
| 2012-06-30 | |
| 2012-03-31 | |
| 2011-12-31 | |
| 2011-09-30 | |
| 2011-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |